40 Years of Topical Tretinoin Use in Review

June 2013 | Volume 12 | Issue 6 | Original Article | 638 | Copyright © June 2013

Hilary E. Baldwin MD,a Marge Nighland BS,b Clare Kendall MA,c David A. Mays PharmD MBA,c Rachel Grossman MD,b,c and Joan Newburger PhDc

aSUNY Downstate Medical Center, Brooklyn, NY bValeant Dermatology, a subsidiary of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ cJohnson & Johnson Consumer & Personal Products Worldwide, Skillman, NJ

table 11


Editorial assistance for this manuscript was provided by Erin Falconer PhD of The Lockwood Group. Funding for editorial assistance was provided by Valeant Dermatology, a subsidiary of Valeant Pharmaceuticals North America LLC, Bridgewater, NJ.
H.E. Baldwin MD has participated on an advisory board for Galderma and as a speaker for Allergan, Galderma, Medicis, Onset Dermatologics, and Valeant. M. Nighland BS is an employee and stockholder of Johnson & Johnson. C. Kendall MA and D.A. Mays PharmD MBA are employees of Johnson & Johnson Group of Consumer Companies, Inc. R. Grossman MD is a Johnson & Johnson stockholder and employee of Valeant Pharmaceuticals North America LLC. J. Newburger PhD was an employee of Johnson & Johnson at the time of manuscript development and is a current stockholder of Johnson & Johnson.


  1. Haas AA, Arndt KA. Selected therapeutic applications of topical tretinoin. J Am Acad Dermatol. 1986;15(4 Pt 2):870-877.
  2. Stüttgen G. Historical perspectives of tretinoin. J Am Acad Dermatol. 1986;15(4 Pt 2):735-740.
  3. Kligman AM, Fulton JE Jr, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol. 1969;99(4):469-476.
  4. Kligman AM. The treatment of acne with topical retinoids: one man’s opinions. J Am Acad Dermatol. 1997;36(6 Pt 2):S92-S95.
  5. US Food and Drug Administration. Drugs@FDA: FDA-approved drug products. [Retin-A 1971]. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed December 6, 2012.
  6. Thorne EG. Topical tretinoin research: an historical perspective. J Int Med Res. 1990;18(Suppl 3):18C-25C.
  7. US Food and Drug Administration. Drugs@FDA: FDA-approved drug products. [Renova 1995]. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed December 6, 2012.
  8. Webster GF, Rawlings AV, eds. Acne and Its Therapy. New York, NY: Informa Healthcare USA, Inc. 2007.
  9. Retin-A Micro Pump (tretinoin gel) 0.04%/0.1% [package insert]. Los Angeles, CA: Ortho Dermatologics, a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2010.
  10. Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4(1):41-47.
  11. Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids.Curr Pharm Des. 2000;6(9):919-931.
  12. Fisher GJ, Datta SC, Talwar HS, et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature. 1996;379(6563):335-339.
  13. Francz PI, Conrad J, Biesalski HK. Modulation of UVA-induced lipid peroxidation and suppression of UVB-induced ornithine decarboxylase response by all-trans-retinoic acid in human skin fibroblasts in vitro. Biol Chem. 1998;379(10):1263-1269.
  14. Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol. 1993;129(4):415-421.
  15. Kang S, Bergfeld W, Gottlieb AB, et al. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am J Clin Dermatol. 2005;6(4):245-253.
  16. Bhawan J, Gonzalez-Serva A, Nehal K, et al. Effects of tretinoin on photodamaged skin. A histologic study. Arch Dermatol. 1991;127(5):666-672.
  17. Ebanks JP, Wickett RR, Boissy RE. Mechanisms regulating skin pigmentation: the rise and fall of complexion coloration. Int J Mol Sci. 2009;10(9):4066-4087.
  18. Eichner R, Kahn M, Capetola RJ, Gendimenico GJ, Mezick JA. Effects of topical retinoids on cytoskeletal proteins: implications for retinoid effects on epidermal differentiation. J Invest Dermatol. 1992;98(2):154-161.
  19. Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical retinoids. Their uses in dermatology. Dermatol Clin. 1993;11(1):107-115.
  20. Houle B, Rochette-Egly C, Bradley WE. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells.Proc Natl Acad U S A. 1993;90(3):985-989.
  21. Li M, Song S, Lippman SM, et al. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene. 2002;21(3):411-418.
  22. Lotan R. Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res. 1994;54(7 Suppl):S1987-S1990.
  23. Bérard J, Laboune F, Mukuna M, Massé S, Kothary R, Bradley WE. Lung tumors in mice expressing an antisense RARβ2 transgene. FASEB J. 1996;10(9):1091-1097.
  24. Treuting PM, Chen LI, Buetow BS, et al. Retinoic acid receptor β2 inhibition of metastasis in mouse mammary gland xenografts. Breast Cancer Res Treat. 2002;72(1):79-88.
  25. Xu XC. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 2007;253(1):14-24.
  26. Webster GF. Evidence-based review: fixed-combination therapy and topical retinoids in the treatment of acne. J Drugs Dermatol. 2011;10(6):636-644.
  27. Biro DE, Shalita AR. Clinical aspects of topical retinoids. Skin Pharmacol. 1993;6(Suppl 1):53-60.
  28. Abramovits W, Oquendo M, Gupta AK. Veltin gel (clindamycin phosphate 1.2% and tretinoin 0.025%). Skinmed. 2011;9(1):49-51.
  29. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369-381.
  30. Eichenfield LF, Nighland M, Rossi AB, et al. Phase 4 study to assess tretinoin pump for the treatment of facial acne. J Drugs Dermatol. 2008;7(12):1129-1136.
  31. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther. 1992;14(6):773-780.
  32. Schmidt N, Gans EH. Clindamycin 1.2% tretinoin 0.025% gel versus clindamycin gel treatment in acne patients: a focus on Fitzpatrick skin types. J Clin Aesthet Dermatol. 2011;4(6):31-40.
  33. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(Suppl 1):S1-S37.